Sponsors face growing competition for clinical trial sites, making “sponsor of choice” status critical. Bristol Myers Squibb illustrates this with a three-part strategy: master clinical trial agreements, non-binding rate cards for faster start-up, and a unified payment model. Payment delays can strain site relationships, slow enrollment, and harm goodwill, so timely, transparent payments are key. BMS adopted IQVIA Clinical Trial Payments (CTP) globally, replacing fragmented systems with a standardized model that stabilizes cash flow, improves forecasting, and enhances compliance. Sites benefit from efficiency, reduced burden, and stronger collaboration with sponsors.

Join for free to read